Eli Lilly will be allowed to intervene in a case over whether FDA was right to remove tirzepatide, the active ingredient its GLP-1 drugs, from the drug shortage list, allowing it to advance a broader argument that FDA is violating the law by allowing compounding of drugs that have not been added to the 503A bulks list under an interim policy. The Outsourcing Facilities Association, the plaintiff in the case, initially opposed Lilly’s motion to intervene in the case but...